Table 2

Summary of combination chemotherapy trials for advanced and metastatic neuroendocrine tumours

Type of study Regimen N ORR (%) Response duration (months) Median survival (months) References
Gastrointestinal
 Ph II STZ+5FU 42 33 – – Moertel & Hanley (1979)
 Ph II 5FU+cyclophosphamide 47 26 – – Moertel & Hanley (1979)
 Ph II STZ+5FU 80 22 8 16 Engstrom et al. (1984)
 Ph II STZ+Dox+5FU+cyclophosphamide 56 31 – – Bukowski et al. (1987)
 Ph II STZ+5FU+cyclophosphamide 9 22 – 10.8 Bukowski et al. (1987)
 Ph II STZ+5FU 27 16 5.3 24.3 Sun et al. (2005)
 Ph II Dox+5FU 25 16 4.5 15.7 Sun et al. (2005)
Pancreatic
 Randomised STZ+5FU 42 63 17 26 Moertel et al. (1980)
 Ph II Dox+5FU+cisplatin 15 14 27 Rougier et al. (1991)
 Ph II Chlorozotocin+5FU 44 36 11 Bukowski et al. (1992)
 Randomised STZ+Dox 36 69 18 26 Moertel et al. (1992)
 Randomised STZ+5FU 33 45 14 18 Moertel et al. (1992)
 Retrospective STZ+Dox 16 6 18 – Cheng & Saltz (1999)
 Retrospective STZ+Dox 16 6 3.9 20.2 McCollum et al. (2004)
 Retrospective STZ+Dox+5FU 84 39 9.3 – Kouvaraki et al. (2004)
 Ph II STZ+Dox+5FU 11 55 15 21 Rivera & Ajani (1998)
 Ph I/II 5FU+dacarbazine+epirubicin 15 27 10 Bajetta et al. (1998)
 Ph II Tem+thalidomide 29 (11) 25 (45) NR Kulke et al. (2006a)
 Ph II Tem+Cap 17 71 Strosberg et al. (2008)
 Ph II Cisplatin+etoposide 11 45 Fjallskog et al. (2001)
Anaplastic
 Ph II Cisplatin+etoposide 18 67 8 16 Moertel et al. (1991)
 Retrospective Cisplatin+etoposide 41 42 9.2 15 Mitry et al. (1999)
 Ph II Cisplatin+etoposide 4 67 Fjallskog et al. (2001)
 Ph II Carboplatin+paclitaxel+etoposide 78 53 – 14.5 Hainsworth et al. (2006)

This Article

  1. Published online before print December 11, 2009, doi: 10.1677/ERC-09-0108 Endocr Relat Cancer vol. 17 no. 1 R75-R90
  1. AbstractFree
  2. Figures Only
  3. Full Text
  4. Full Text (PDF)

New Articles: issue in progress

  1. July 2017, 24 (7)
  1. Current Issue
  1. Alert me to new issues of Endocrine-Related Cancer

Most